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DCE = dynamic contrast-enhanced; MR = magnetic resonance; MRI = magnetic resonance imaging; MRS = magnetic resonance spectroscopy;
MRSI = magnetic resonance spectroscopic imaging; SVS = single-voxel spectroscopy; tCho = total choline-containing compounds; [tCho] = con-
centration of total choline-containing compounds.
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Abstract
A technique called in vivo magnetic resonance spectroscopy (MRS)
can be performed along with magnetic resonance imaging (MRI) to
obtain information about the chemical content of breast lesions. This
information can be used for several clinical applications, such as
monitoring the response to cancer therapies and improving the
accuracy of lesion diagnosis. Initial MRS studies of breast cancer
show promising results, and a growing number of research groups
are incorporating the technique into their breast MRI protocols. This
article introduces 1H-MRS of the breast, reviews the literature,
discusses current methods and technical issues, and describes
applications for treatment monitoring and lesion diagnosis.
Introduction
The first in vivo magnetic resonance spectroscopy (MRS)
studies of breast measured resonances from phosphorus
atoms (31P). These studies showed that measurable variations
in phospholipid metabolism could be detected and used for
diagnosing cancer and monitoring the response to treatment
(reviewed in [1,2]). More recently, there has been growing
interest in breast cancer research using hydrogen (1H)-MRS,
because of its higher sensitivity than 31P-MRS. The first
breast  1H-MRS reports focused on the diagnostic utility of
the water : fat ratio in the breast [3-5], but subsequent
studies did not find this ratio to be a useful diagnostic metric
[6,7]. However, several studies performed with 1H-MRS
noted that a resonance from choline-containing compounds
(tCho) was commonly present in malignant lesions but not in
benign or normal tissues [4,6-11]. Figure 1 shows a repre-
sentative example of a localized 1H spectrum of an invasive
ductal carcinoma, with the tCho resonance indicated.
Ex vivo studies have been performed to identify the different
choline compounds giving rise to the tCho resonance at a
chemical shift of 3.2 ppm. High-resolution 1H spectra
acquired from biopsy tissues have shown that the tCho
resonance is actually a superposition of several resonances
[12-14]. The primary constituents are those with a trimethyl-
amine moiety, R–(CH2)2–N+–(CH3)3, including free choline,
phosphocholine, and glycerophosphocholine. Other
metabolites possibly contributing include taurine, glucose,
phosphoethanolamine, and myo-inositol [14]. The choline
head groups associated with semi-mobile lipids may also
contribute. These resonances can be separated in ex vivo
studies with high-resolution magnetic resonance (MR)
spectrometers, but in vivo these peaks are substantially
broadened, and at fields as high as 4 T these resonances are
generally indistinguishable. Consequently, the simplified
approach used in studies in vivo is to treat the 3.2 ppm
spectral peak as a single resonance.
Numerous in vivo, ex vivo, and in vitro studies have shown
that this tCho peak is elevated in neoplastic tissues.
However, the precise mechanisms that produce an elevated
tCho concentration ([tCho]) have not yet been fully identified.
A working hypothesis is that elevated [tCho] is an indicator of
increased cellular proliferation. The largest component
contributing to the tCho peak from neoplastic tissue is
phosphocholine, a known precursor of membranes. Thus, the
increased [tCho] in neoplastic tissues may be a reflection of
increased membrane turnover by replicating cells. This is
probably an oversimplified view, because [tCho] can be
modulated by numerous changes in enzymatic activity and
fluxes in biosynthetic and catabolic pathways in which choline
compounds serve as both precursors and catabolites. This is
an active area of research.
In spite of this seemingly complex situation, several groups
have successfully shown that tCho can be used as an
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indicator of malignancy with clinical 1.5 T scanners. Some
groups have also shown that the tCho peak decreases or
disappears in response to chemotherapy treatment. The
results of these studies are encouraging, and with continued
technical development it seems likely that MRS will become a
useful tool in detecting and managing breast cancer.
Technical issues
Historically, 1H-MRS research has been focused mainly on the
brain, in part because use of this technique on the brain poses
fewer technical challenges than on other organ sites. Most of
the research and development in the field of MR has been
focused on brain applications; as a result, commercial MR
systems are generally better optimized for brain rather than
breast studies. As a result of increased interest by clinicians and
researchers in the application of MR to breast cancer, many
technical advances are now taking place that are improving the
quality and reliability of breast magnetic resonance imaging
(MRI) and MRS. For example, significant improvement in signal :
noise ratio can be realized by using multi-channel phased-array
coils that are now commercially available.
Single-voxel spectroscopy
Most breast MRS studies so far have used single-voxel
spectroscopy (SVS) to localize the chemical signals to a single,
cuboid volume (called a voxel) centered on the lesion of
interest. Our group uses a specialized pulse sequence called
LASER (localization by adiabatic selective refocusing) [15].
This technique has several useful properties; most notably it is
insensitive to radiofrequency field inhomogeneity and provides
clean localization. Although most breast MRS studies have
been done with SVS, other researchers have explored the use
of magnetic resonance spectroscopic imaging (MRSI) as an
alternative [16]. In MRSI, spectra are acquired in a grid. MRSI
has an important advantage: it provides information about the
spatial distribution of metabolites, which is useful for studying
multiple lesions or evaluating the spatial variation of a
metabolite in a heterogeneous lesion. However, MRSI is
technically more challenging than SVS, and quantification of
metabolite levels is more problematic. For these reasons, and
because it is not yet commonly used in the breast, the rest of
the discussion here will focus on SVS.
A typical MRS study is performed immediately after acquiring
dynamic contrast-enhanced (DCE) MR images. Decisions
about the placement of the MRS voxel are usually based on a
review of the lesion morphology and the kinetics of contrast
agent uptake while the patient is still in the magnet. With
SVS, the placement of the voxel is of critical importance. The
voxel should be placed so that it contains as much of the
lesion as possible while excluding other tissues such as
normal fibroglandular or adipose tissue. In studies using MRS
to monitor response to treatment, the voxel size and position
can be adjusted to cover the same anatomical region of the
tumor, decreasing the voxel size as the tumor shrinks.
Lipids
Intense resonances from mobile lipids are a prominent feature
of  1H spectra of breast tissues, whereas these signals are
essentially absent from brain spectra. The amplitude of the
lipid resonance can vary markedly depending on the tissue
heterogeneity. The adipose tissue not directly involved in
breast carcinoma can pose problems for breast MRS. When
trying to place a voxel in a suspect lesion, any adipose tissue
inadvertently included in the voxel creates a partial volume
effect, reducing the effective volume for spectroscopy.
Adipose tissue also limits the ability to optimize (or ‘shim’) the
homogeneity of the magnetic field inside the voxel, which in
turn leads to broad resonances and reduced signal : noise
ratio. Intense lipid resonances can also produce sideband
artefacts that can interfere with MRS measurements. These
artefactual resonances can be larger than the tCho
Figure 1
Example of a localized breast spectrum acquired at 4 T. The image on the left indicates the voxel placement, which covers a rim-enhancing lesion
of invasive ductal carcinoma. The water-suppressed spectrum on the right shows the resonances typically observed in malignant breast lesions.
Quantifying the spectrum by using water as an internal reference produced a measurement of concentration of total choline-containing compounds
of 4.4 ± 0.3 mmol/kg (±SD).151
resonance. To reduce sideband artefacts, our group uses a
method called echo-time averaging, which causes coherent
cancellation of sideband artefacts by averaging spectra
acquired at several different echo-time values [17]. For all
these reasons, it is important to plan voxels carefully to
minimize the amount of adipose tissue included.
Quantification
Although several groups have had success in using the
detectability of tCho to indicate malignancy, this approach
assumes that the MRS measurement sensitivity is roughly
constant from one measurement to the next. However, there
are several factors that make this assumption questionable in
breast MRS, such as variations in voxel size, adipose tissue
content, and coil sensitivity. In our experience at 4 T, we have
found that these factors produce a large variation in
sensitivity [18]. Thus, some form of quantification should be
used to correct for sensitivity variations, or at the very least
exclude those voxels with unusual sensitivity.
A variety of approaches have been used for quantifying MRS
data. We chose to use the intravoxel water resonance as an
internal reference, because this method is robust and
automatically compensates for variations in many factors [18].
Some groups have proposed using an external standard for
referencing [6,19]. This approach also works but requires
additional corrections for voxel size, adipose tissue content,
and coil efficiency. Both internal and external referencing
methods need correction for differences in relaxation rates,
which are difficult to measure in individual subjects.
Applications
Diagnosis
The first and most studied application for breast MRS is to
distinguish benign from malignant lesions before biopsy. The
first published paper on this topic, by Roebuck and colleagues
in 1998 [6], proposed the idea that tCho could be used as a
marker of malignancy. Several papers that followed, listed in
Table 1, continued to use this hypothesis but performed
studies with somewhat different techniques. The overall results
are quite consistent. Katz-Brull and colleagues published a
combined analysis of the first five papers in Table 1 and
reported an overall sensitivity of 83% and specificity of 85%
[20]. These results are very encouraging, especially
considering that the determination of malignancy was done
without considering any other diagnostic or historical
information that would normally be available clinically.
Other publications describing tCho detection in breast
cancers did not report diagnostic specificity and sensitivity
[5,7]. Although the results using a simple detectability hypo-
thesis are encouraging, it seems likely that there are benign
pathologies that also produce detectable levels of tCho.
Indeed, at 1.5 T, a detectable tCho resonance has been
reported in fibroadenomas [8,9,16,21], tubular adenomas
[6,10] and lactating subjects [8,11].
Two recent studies have sought to evaluate whether MRS
can improve the specificity of a diagnostic breast MR exam.
Huang and colleagues appended a single-voxel MRS
measurement and a single-slice T2
*-weighted perfusion
measurement to a conventional DCE-MRI exam [21]. They
found that the addition of MRS increased the specificity of
the exam from 62.5% to 87.5%, and the further addition of
the perfusion measurement raised the specificity to 100%.
Our group recently performed a retrospective blinded-
observer performance study with four readers and 55
subjects to determine whether quantitative MRS could
improve the specificity and sensitivity of a DCE-MRI exam
[22]. In this study we reported that adding quantitative MRS
results to a DCE-MRI exam produced improvements in the
sensitivity, specificity, and accuracy for all readers, and
improved the interobserver agreement between the readers.
Monitoring response to treatment
A second and perhaps more promising application is the use of
breast MRS for predicting response to cancer treatment.
Current clinically available methods such as palpation and
imaging rely on changes in tumor size, which take several
weeks before any changes are detectable. Breast MRS, in
contrast, detects changes in intracellular metabolism that
would occur before any gross morphological change. The first
report using tCho measurements to detect treatment response
in breast cancer was by Jaganathan and colleagues, who
observed that the tCho resonance disappeared or became
smaller in 89% of subjects undergoing chemotherapy [11].
Expanding on this observation, our group performed a study
designed to determine whether changes in [tCho] could
provide a biomarker of clinical response as soon as 24 hours
after the first dose of doxorubicin-based chemotherapy for
locally advanced breast cancer [23]. Of the first 13 patients
who successfully completed the protocol without technical
problems, the change in [tCho] between baseline and
24 hours after the first dose of chemotherapy showed a
significant positive correlation (R = 0.79, P = 0.001) with the
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Table 1
MRS in the diagnostic context
No. of  No.  Sensitivity  Specificity 
Reference cancers benign (%) (%)
[6] 10 7 70 86
[8] 11 11 82 82
[10] 23 15 83 87
[11] 32 14 78 86
[9] 24 6 92 83
[24] 19 16 100 100
[25] 19 27 89 100
[16] 8 7 87 85152
change in lesion size measured at the end of four cycles of
chemotherapy (median duration 67 days; range 65 to
72 days). The change in [tCho] within 24 hours was
significantly different between responders and nonresponders
(P = 0.007) classified with RECIST (Response Evaluation
Criteria in Solid Tumors). These results suggest that the
change in [tCho] within 24 hours after the first dose of the
drug can serve as an early indicator for predicting clinical
response to treatment for locally advanced breast cancer.
Conclusions
The quality and reliability of MRS data will only improve as
further refinements in MR systems and techniques continue
to occur. At present, dissemination of MRS methodology
optimized for breast studies is occurring, and breast MRS
and MRI are rapidly becoming standard capabilities of most
state-of-the-art clinical MR systems with magnets 1.5 T or
stronger. The promising results from multiple institutions
reported so far suggest that MRS, along with MRI, will have
an increased role in the clinical assessment of breast cancer
in the future. However, large multicenter trials are still needed
before the tCho biomarker can be widely used to guide
diagnostic decisions and to predict response to therapy.
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This article is part of a review series on Imaging in breast
cancer, edited by David A Mankoff.
Other articles in the series can be found online at
http://breast-cancer-research.com/articles/
review-series.asp?series=bcr_imaging